Literature DB >> 25616096

Targeted therapy in the treatment of uterine serous carcinoma.

Carlton L Schwab1, Alessandro D Santin.   

Abstract

Entities:  

Keywords:  HER2; PIK3CA; mTOR; targeted therapy; uterine serous carcinoma

Mesh：

Substances：

Year:  2015        PMID： 25616096     DOI： 10.2217/pgs.14.176

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN： 1462-2416            Impact factor:   2.533


× No keyword cloud information.
  3 in total

1.  Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.

Authors:  Emiliano Cocco; Salvatore Lopez; Jonathan Black; Stefania Bellone; Elena Bonazzoli; Federica Predolini; Francesca Ferrari; Carlton L Schwab; Gulden Menderes; Luca Zammataro; Natalia Buza; Pei Hui; Serena Wong; Siming Zhao; Yalai Bai; David L Rimm; Elena Ratner; Babak Litkouhi; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Alessandro D Santin
Journal:  Br J Cancer       Date:  2016-06-28       Impact factor: 7.640

2.  PD-L1 Expression in Endometrial Serous Carcinoma and Its Prognostic Significance.

Authors:  Tao Zhang; Qin Liu; Yingfan Zhu; Songfa Zhang; Qiaohua Peng; Amanda Louise Strickland; Wenxin Zheng; Feng Zhou
Journal:  Cancer Manag Res       Date:  2021-12-14       Impact factor: 3.989

Review 3.  Pathogenesis and Clinical Management of Uterine Serous Carcinoma.

Authors:  Li Zhang; Suet Ying Kwan; Kwong Kwok Wong; Pamela T Solaman; Karen H Lu; Samuel C Mok
Journal:  Cancers (Basel)       Date:  2020-03-14       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.